Yahoo Web Search

  1. International Stem Cell Corp. ISCO, -0.71% Intellia Therapeutics, Inc. NTLA, -2.01% Omeros Corporation OMER, +3.33% BrainStorm Cell Therapeutics Inc. BCLI, ...

  2. BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule

    Zacks Small Cap Research via Yahoo Finance7 days ago

    The company recorded R&D expenses for the first quarter of 2017 and 2018 net of research and development grants from the IIA and CIRM. R&D expenses for the first quarter of 2018 were $0.98 million ...

  1. 2 results